Oral Oncology
Volume 45, Issue 12 , Pages 1021-1027 , December 2009

Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses

  • Kengo Saito

      Affiliations

    • Department of Molecular Virology (E2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • ,
  • Hiroshi Shirasawa

      Affiliations

    • Department of Molecular Virology (E2), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • ,
  • Naohisa Isegawa

      Affiliations

    • Laboratory Animal Center (G3), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • ,
  • Masashi Shiiba

      Affiliations

    • Department of Clinical Molecular Biology (M8), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • ,
  • Katsuhiro Uzawa

      Affiliations

    • Department of Clinical Molecular Biology (M8), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • ,
  • Hideki Tanzawa

      Affiliations

    • Department of Clinical Molecular Biology (M8), Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuou-ku, Chiba 260-8670, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 226 2300; fax: +81 43 226 2151.

Received 17 July 2009 ,Revised 29 August 2009 ,Accepted 2 September 2009.

References 

  1. Casiglia J, Woo SB. A comprehensive review of oral cancer. Gen Dent. 2001;49(1):72–82
  2. Tankere F, Camproux A, Barry B, Guedon C, Depondt J, Gehanno P. Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. Laryngoscope. 2000;110(12):2061–2065
  3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin. 2003;53(1):5–26
  4. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res. 2003;82(1):11–16
  5. Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer. Curr Opin Oncol. 2002;14(3):334–342
  6. Wakasa T, Inoue T, Kawai N, Murakami J, Kishi K, Fukui K. The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. Br J Radiol. 2002;75(896):657–662
  7. Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol. 1998;16(3):1054–1059
  8. Saraswathi TR, Kavitha B, Vijayashree Priyadharsini J. Gene therapy for oral squamous cell carcinoma: an overview. Indian J Dent Res. 2007;18(3):120–123
  9. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9(1):64–71
  10. Kerr D. Clinical development of gene therapy for colorectal cancer. Nature Rev Cancer. 2003;3(8):615–622
  11. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol. 2003;4(7):415–422
  12. McCormick F. Cancer gene therapy: fringe or cutting edge?. Nature Rev Cancer. 2001;1(2):130–141
  13. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol. 2001;3(8):745–750
  14. Imperiale MJ, Kao HT, Feldman LT, Nevins JR, Strickland S. Common control of the heat-shock gene and early adenovirus genes – evidence for a cellular E1A-like activity. Mol Cell Biol. 1984;4(5):867–874
  15. Working PK, Lin A, Borellini F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene. 2005;24(52):7792–7801
  16. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3(6):639–645
  17. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell. 2003;4(1):7–11
  18. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev Cancer. 2005;5(12):965–976
  19. Thorne SH, Hermiston T, Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol. 2005;32(6):537–548
  20. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science. 1998;282(5392):1332–1334
  21. Norman KL, Lee PW. Reovirus as a novel oncolytic agent. J Clin Invest. 2000;105(8):1035–1038
  22. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med. 2000;6(7):821–825
  23. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003;4(4):263–275
  24. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274(5286):373–376
  25. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nature Med. 2000;6(10):1134–1139
  26. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1995;1(9):938–943
  27. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res. 1994;54(15):3963–3966
  28. Comins C, Heinemann L, Harrington K, Melcher A, De Bono J, Pandha H. Reovirus: viral therapy for cancer ‘as nature intended’. Clin Oncol. 2008;20(7):548–554
  29. Kirn D, Hermiston T, McCormick F. ONYX-015: clinical data are encouraging. Nature Med. 1998;4(12):1341–1342
  30. Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluororacil in patients with recurrent head and neck cancer. Nature Med. 2000;6(8):879–885
  31. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol. 2001;19(2):289–298
  32. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 2001;8(21):1618–1626
  33. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, et al. Hepatic arterial infusion of a replication selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 2002;62(21):6070–6079
  34. Liu TC, Hwang TH, Bell JC, Kirn DH. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther. 2008;16(6):1006–1008
  35. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res. 2007;67(2):429–432
  36. Chiocca EA. Oncolytic viruses. Nat Rev Cancer. 2002;2(12):938–950
  37. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12(4):141–161
  38. Ring CJ. Cytolytic viruses as potential anti-cancer agents. J Gen Virol. 2002;83:491–502
  39. Ward TG, Huebner RJ, Rowe WP, Ryan RW, Bell JA. Production of pharyngoconjunctival fever in human volunteers inoculated with APC viruses. Science. 1995;122(3179):1086–1087
  40. Mitsui Y, Hanabusa J, Minoda R, Ogata S. Effect of inoculating adenovirus (APC virus) type 8 into human volunteers. Am J Ophthalmol. 1957;43:84–90
  41. Huneycutt BS, Bi Z, Aoki CJ, Reiss CS. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol. 1993;67(11):6698–6706
  42. Stojdl DF, Abraham N, Knowles S, Marius R, Brasey A, Lichty BD, et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol. 2000;74(20):580–585
  43. Southam CM. Present status of oncolytic virus studies. Trans NY Acad Sci. 1960;22:656–673
  44. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res. 2004;10(16):5299–5312
  45. Martuza RL. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest. 2000;105(7):841–846
  46. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA. 1996;93(21):11307–11312
  47. Chou J, Kern ER, Whitley RJ, Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science. 1990;250(4985):1262–1266
  48. Chun YS, Adusumilli PS, Fong Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia. 2005;10(4):311–318
  49. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci. 2007;28(7):326–333
  50. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 2001;8(10):746–759
  51. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med. 2001;7(7):781–787
  52. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19(56):6660–6668
  53. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng. 2004;23(12):1666–1670
  54. Russell SJ. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol. 1994;5(6):437–443
  55. Russell SJ. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer. 1994;30A(8):1165–1171
  56. McCormick F. Future prospects for oncolytic therapy. Oncogene. 2005;24(52):7817–7819
  57. Vähä-Koskela MJ, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254(2):178–216
  58. Aghi M, Martuza RL. Oncolytic viral therapies: the clinical experience. Oncogene. 2005;24(52):7802–7816
  59. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res. 2000;6(3):798–806
  60. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys. 2006;66(3):637–646
  61. Yotnda P, Chen DH, Chiu W, Piedra PA, Davis A, Templeton NS, et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther. 2002;5(3):233–241
  62. Croyle MA, Chirmule N, Zhang Y, Wilson JM. ‘‘Stealth” adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol. 2001;75(10):4792–4801
  63. O’Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999;10(8):1349–1358
  64. Siemens DR, Elzey BD, Lubaroff DM, Bohlken C, Jensen RJ, Swanson AK, et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol. 2001;166(2):731–735
  65. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000;60(22):6359–6366
  66. Herrlinger U, Kramm CM, Aboody-Guterman KS, Silver JS, Ikeda K, Johnston KM, et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 1998;5(6):809–819
  67. Neff-LaFord HD, Vorderstrasse BA, Lawrence BP. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol. 2003;226(1):54–64
  68. Snow GB. Evaluation and staging of the patient with head and neck cancer. Churchill Livingstone, Inc.: New York; 1989;p. 17–38
  69. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene. 1995;10(6):1217–1227
  70. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res. 1993;53(19):4477–4480
  71. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 1994;54(2):321–326
  72. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003;21(24):4546–4552
  73. Brown SM, Harland J, MacLean AR, Podlech J, Clements JB. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol. 1994;75:2367–2377
  74. Lasner TM, Kesari S, Brown SM, Lee VM, Fraser NW, Trojanowski JQ. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol. 1996;55(12):1259–1269
  75. Randazzo BP, Kesari S, Gesser RM, Alsop D, Ford JC, Brown SM, et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology. 1995;211(1):94–101
  76. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol. 1997;108(6):933–937
  77. Kesari S, Randazzo BP, Valyi-Nagy T, Huang QS, Brown SM, MacLean AR, et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest. 1995;73(5):636–648
  78. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al. Use of a ‘‘replication-restricted” herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 1997;57(3):466–471
  79. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR, Molnar-Kimber KL. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther. 1999;10(18):3013–3029
  80. Mace AT, Harrow SJ, Ganly I, Brown SM. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol. 2007;127(8):880–887
  81. Mace AT, Ganly I, Soutar DS, Brown SM. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck. 2008;30(8):1045–1051
  82. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 2006;12(22):6737–6747
  83. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol. 2002;20(9):2251–2266
  84. Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001. p. 917–962.
  85. Tseng JC, Levin B, Hirano T, Yee H, Pampeno C, Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst. 2002;94(23):1790–1802
  86. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol. 1992;66(8):4992–5001
  87. van den Brûle FA, Castronovo V, Ménard S, Giavazzi R, Marzola M, Belotti D, et al. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur J Cancer. 1996;32A(9):1598–1602
  88. Al-Saleh W, Delvenne P, van den Brule FA, Menard S, Boniver J, Castronovo V. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J Pathol. 1997;181(3):287–293
  89. Unno Y, Shino Y, Kondo F, Igarashi N, Wang G, Shimura R, et al. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin Cancer Res. 2005;11(12):4553–4560
  90. Lundstrom K. Alphavirus vectors for gene therapy applications. Curr Gene Ther. 2001;1(1):19–29
  91. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. BioTechnology. 1991;9(12):1356–1361
  92. Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV. Sindbis virus: an efficient broad host range vector for gene expression in animal cells. Science. 1989;243(4895):1188–1191
  93. Davis NL, Willis LV, Smith JF, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989;171(1):189–204
  94. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol. 2003;21(3):117–122
  95. Fujimoto Y, Mizuno T, Sugiura S, Goshima F, Kohno S, Nakashima T, et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol. 2006;126(10):1115–1117

PII: S1368-8375(09)00908-7

doi: 10.1016/j.oraloncology.2009.09.002

Oral Oncology
Volume 45, Issue 12 , Pages 1021-1027 , December 2009

Article Tools

* Image Usage & Resolution